Skip to content
Disclosery

Versant Venture Management, LLC

Follow

13F filer, CIK 1560009, San Francisco, CA

Versant Venture Management, LLC reported $151,060,501 across 7 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-12.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-048719

Period
2025-12-31
Reported value
$151M
Holdings
7
Top 10 weight
100%
New
0
Sold out
2

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
GLUEreduced-1,270,235-$19.9M
REPARE THERAPEUTICS INCexited-2,646,657-$4.66M
Adverum Biotechnologies, In…exited-506,821-$2.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001193125-26-048719, largest first. % of portfolio is the value over $151,060,501, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 5,652,922 shares; 2025Q1: 5,652,922 shares; 2025Q2: 5,652,922 shares; 2025Q3: 5,652,922 shares; 2025Q4: 4,382,687 shares 4,382,687$68.7M45.49%-1,270,235Timeline
LENZLENZ THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,656,888 shares; 2025Q4: 2,656,888 shares 2,656,888$42.5M28.14%0Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,525,820 shares; 2025Q3: 1,525,820 shares; 2025Q4: 1,525,820 shares 1,525,820$23.5M15.59%0Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 498,558 shares; 2024Q4: 498,558 shares; 2025Q1: 498,558 shares; 2025Q2: 498,558 shares; 2025Q3: 148,831 shares; 2025Q4: 148,831 shares 148,831$7.8M5.17%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 918,163 shares; 2024Q4: 918,163 shares; 2025Q1: 918,163 shares; 2025Q2: 542,628 shares; 2025Q3: 542,628 shares; 2025Q4: 542,628 shares 542,628$6.2M4.11%0Timeline
SKYESKYE BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,007,704 shares; 2024Q4: 2,007,704 shares; 2025Q1: 2,007,704 shares; 2025Q2: 2,007,704 shares; 2025Q3: 2,007,704 shares; 2025Q4: 2,007,704 shares 2,007,704$1.51M1%0Timeline
Tempest Therapeutics, Inc.Tempest Therapeutics, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 3,507,055 shares; 2025Q1: not reported; 2025Q2: 269,772 shares; 2025Q3: 269,772 shares; 2025Q4: 269,772 shares 269,772$774K0.51%0

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
REPARE THERAPEUTICS INCREPARE THERAPEUTICS INC2,646,657$4.66Mshares
Adverum Biotechnologies, In…Adverum Biotechnologies, Inc.506,821$2.3Mshares

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-048719 base2026-02-12acceptance time not in the bulk data set